Business Wire

Denodo Adds to Executive Team with Key Appointments: Daniel Lender Joins as Chief Financial Officer and Stephen Welles as Chief Legal Officer

10.11.2022 11:00:00 EET | Business Wire | Press release

Share

Denodo, a leader in data management, today announced two key additions to its executive team to help to guide Denodo through its next phase of growth: Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer. Mr. Lender and Mr. Welles will lead all of Denodo’s global financial and legal strategy and operations, reporting directly to Denodo’s Chief Executive Officer, Angel Viña.

“We’re excited to welcome Daniel as our new CFO and Stephen as our new CLO,” said Angel Viña, CEO and Founder of Denodo. “Daniel brings extensive financial and operational experience in enterprise software to our executive team and Stephen adds his broad and deep expertise in legal matters. These two key appointments strengthen our executive team and will be a great asset to Denodo as we continue to grow our global business.”

Daniel Lender is the newest addition to Denodo’s executive leadership team and brings more than 30 years of enterprise software and financial markets experience to his role. Mr. Lender joins Denodo after a long tenure with QAD Inc., a leading provider of next generation manufacturing and supply chain management solutions in the cloud, where he served as executive vice president and chief financial officer.

“I am absolutely thrilled to join Denodo at this stage,” said Daniel Lender. “With data growing at an exponential rate and multi-cloud platforms becoming the norm, I believe Denodo, with its unique and proprietary platform, is well positioned to continue its growth path and help its customers unlock value from their data. I look forward to working with the Denodo leadership team to help fuel Denodo’s next phase of growth.”

Stephen Welles brings more than 25 years of experience to his new position as Chief Legal Officer. He joined Denodo from Wilson Sonsini Goodrich & Rosati, the premier legal advisor to technology, life sciences, and other growth enterprises worldwide, where he was a senior counsel. Before that, he was the senior vice president and general counsel at Oplink Communications, an optical networking equipment company with more than 3,000 employees worldwide.

“Denodo has a bright future and I am excited to be a part of the team,” said Stephen Welles. “Denodo’s mission to help enterprises become data-driven organizations is an important one, and it will continue to drive Denodo’s growth.”

Denodo was recognized as a Leader in the 2022 Gartner® Magic Quadrant™ for Data Integration Tools for a third year in a row, and in the Forrester Wave™: Enterprise Data Fabric, Q2 2022 for a second year in a row. Denodo is the fastest growing vendor among the top 10 data integration vendors according to Gartner Market Share Analysis: Data Integration Software, Worldwide, 2021. Denodo also has been consistently receiving Customers’ Choice distinction in the Gartner Peer Insights 'Voice of the Customer': Data Integration Tools report for the last two years, showcasing how positively Denodo customers perceive the value of the product, services and support offered by Denodo.

Please tweet: News: @denodo adds to executive team - Daniel Lender as Chief Financial Officer and Stephen Welles as Chief Legal Officer to drive next phase of growth for #datamanagement and #dataintegration leader

About Denodo

Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye